ANR / France 2030: France Vaccins call, Senior Chairs in Vaccine Innovation (CSIV)
Provide a recognised senior vaccinology researcher with a chair of up to five years and a dedicated team, at a French host institution.
At a glance
- Programme
- France 2030: France Vaccins programme, acceleration strategy on emerging infectious diseases and CBRN threats (Innovation Santé 2030 plan)
- Territory
- France (French host institution); candidates holding a position in France or abroad
- Beneficiaries
- Internationally recognised top-level researcher in vaccinology; agreement concluded with a French higher education and research institution or healthcare institution, public or private non-profit
- Type of aid
- France 2030 funding allocation, paid by ANR to the host institution according to the contract's payment schedule; eligible costs set by forthcoming financial regulations
- Amount / rate
- Up to €3.3 million per chair, over a maximum of five years; indirect costs covered by a flat rate of up to 20% of eligible direct costs; programme budget of €10 million for 3 to 4 chairs
- Availability
- Open since 10 November 2026 at 16:00; complete application by 28 January 2027 at 11:00; financial regulations, submission website and templates listed as coming soon on 11 November 2026
Information up to date as of 11 November 2026, valid until 28 January 2027. Scheme conditions change: check with the funding body or ask us for confirmation.
The France Vaccins programme of France 2030 (the French State's investment plan) is opening, through a call for applications operated by ANR (the French National Research Agency), three to four Chaires Séniors en Innovation Vaccinale (Senior Chairs in Vaccine Innovation, CSIV), intended to place researchers already recognised in vaccinology, holding a position in France or abroad, in a leadership role. Each chair, lasting up to five years, can receive up to €3.3 million, paid to the host institution, from a programme with a budget of €10 million. Open since 10 November 2026 at 16:00, the call closes on 28 January 2027 at 11:00 (Paris time); as of 11 November 2026, ANR's page still lists the financial regulations, the submission website and the application templates as "coming soon".
Which projects are funded?
The CSIV aim to bring forward the next generation of leaders in vaccine innovation: scientists able to meet the operational challenges of pandemic response, to lead interdisciplinary projects that remove the barriers to the accelerated development of vaccines against emerging or re-emerging pathogens, and to anticipate the technological, regulatory and societal trends in the field. Each chair must strengthen, at the same time, the holder's research scope, their involvement in training and in passing on knowledge, and their operational impact, particularly in health crisis preparedness or response scenarios.
Proposals address either barriers in the vaccine development chain (in line with the 100 Days Mission or from a European sovereignty perspective) or, in a more integrative way, questions of vaccination strategy (for example from a One Health perspective). They must contribute to the continuum between the programmes of the national strategy (the PEPR priority research programmes MIE and PREZODE, the CATRIEM consortium, the Infectious Diseases Cluster and France Vaccins initiatives, the I-REIVAC Emergence clinical network, the graduate schools of research dedicated to emerging infectious diseases).
The project incorporates at least three of the following six directions:
- enable the accelerated development of new vaccine candidates targeting one or more families of priority pathogens identified by the WHO R&D Blueprint for Epidemics group;
- increase direct partnerships between academic research and industry on critical segments of the development chain, for example through joint laboratories or co-development projects, national or international;
- promote the use of national technological (INBS) and/or clinical (I-REIVAC) infrastructures;
- strengthen or establish higher education and transfer hubs in vaccine technologies, in particular via one of the three graduate schools of research (1H-EID, EID@Lyon, UNITEID), the ADVAC advanced international course or technology transfer schemes (PUI, SATT, etc.);
- develop partnerships between mainland France and the overseas departments and regions;
- develop partnerships with countries with intermediate or limited resources.
The call text cites, as examples, three challenges that combine scientific and clinical innovation, public health and societal issues:
- generic and modular vaccine approaches to respond rapidly to pathogens X (structural biology, artificial intelligence and immunoinformatics for immunogen design, systems immunology, formulation and adjuvants, predictive human models, scientific-economic or regulatory studies), with proof of feasibility conducted primarily on emerging infectious diseases;
- the protection of vulnerable populations (older people, immunocompromised people or people with comorbidities), including research on simplified vaccination protocols to facilitate access to vaccination for disadvantaged populations, as well as adherence;
- vaccines or vaccination strategies against zoonotic diseases, taking into account scientific, economic and territorial issues, including societal acceptability.
Keywords of the call: vaccine development, pandemic preparedness, zoonoses, technological innovation, adaptable vaccine platforms, immunoinformatics, biosecurity and biodefence, acceptability.
Who can apply?
The chair is awarded to an individual, on the basis of their scientific project, under an agreement with the institution that hosts them.
- Chair holder (lead applicant): a top-level researcher, already internationally recognised in their field of research and expertise in vaccinology (for example preclinical models, bioengineering, translational and clinical development), who still has at least a dozen years ahead of them before the end of their career in France (admissibility criterion). Their track record must meet the ERC Advanced evaluation criteria. They must have experience in the advanced training of professionals in the vaccine field (master's, pharmacy, medicine, veterinary medicine or doctorate) and undertake to train the sector's future experts in France. They set up a team fully dedicated to the project. Only one application is accepted per lead applicant, who submits it personally on the submission website.
- Mobility and status: the candidate may already hold a position in a French public or industrial laboratory, and either grow on their current site or move to a new environment, or hold a position abroad and wish to settle in France; a successful applicant coming from abroad settles in a public environment of their choice. Successful applicants undertake to submit, within three years and according to their level, an application for additional European or international funding (ERC Advanced, Proof-of-concept or Synergy, IHI, CEPI or other research foundations). They join the steering committee of the France Vaccins programme.
- Host institution (managing institution): a French higher education and research institution (universities, research organisations, etc.) or a healthcare institution, public or private non-profit. It signs the agreement, handles administrative and financial management and provides the chair holder with the necessary resources. The application specifies the laboratory space, access to shared infrastructure and services, and administrative support, with a letter of commitment from the heads of the host structures; these conditions must be able to evolve with the size of the team. The institution also presents the solutions envisaged to secure the successful applicant's long-term settlement in France, which will be reviewed at mid-term. The call text reserves "this funding" (the sentence follows the one on the flat rate for indirect costs) for research organisations, research and higher education institutions, healthcare institutions and their groupings; private institutions contributing to the public service missions of higher education and research (Article L. 732-1 of the Education Code) may possibly be funded, after analysis by ANR, the opinion of the MESRE (the French ministry of higher education, research and space) and approval by the SGPI (the General Secretariat for Investment).
- Companies and foreign institutions: they may be partners in the project, but receive no funding for their participation. The involvement of a company makes a consortium agreement mandatory.
- Other partner institutions: each signs its letter of commitment in the administrative and financial document. The call text provides that they sign the consortium agreement even without a share of the funding; whether a French partner institution may receive a share is to be confirmed in the financial regulations.
Which costs are eligible?
The chair must give the holder the means to conduct an ambitious research programme, with a high level of scientific autonomy and appropriate resources: to create or expand their team, fully dedicated to the project, broaden their research scope, get involved in training and increase their visibility for international and industrial collaborations.
- Eligible costs will be specified in the call's financial regulations, listed as "coming soon" on 11 November 2026: the types of cost items and the calculation rules are to be confirmed in these regulations.
- Indirect costs (premises, administration, IT, etc.): the host institution may receive a flat rate of up to 20% of eligible direct costs.
- The funding is used exclusively for the project described in the application and cannot be transferred to another researcher.
How much funding is available?
- Funding requested: up to €3.3 million per chair (admissibility criterion). The call text does not say whether this ceiling includes the flat rate for indirect costs: to be confirmed in the financial regulations.
- Duration: five years maximum.
- Programme budget: €10 million for three to four chairs, according to ANR's page.
- Payment: funding allocation disbursed by ANR for the coordinating institution, according to the payment schedule set out in the contract.
- Chair holders undertake to seek additional funding, in particular from the European Union (ERC, Marie Curie, IHI, etc.) and from foundations, managed according to the host institution's rules.
Main selection criteria
An independent scientific evaluation committee, set up by ANR and able to call on external experts, examines the admissible applications and may interview several candidates before selecting the three or four best proposals. It ranks them A (recommended for funding) or B; the Prime Minister takes the decision after receiving the opinions of the Committee for Higher Education, Research and Innovation Ecosystems (CEERI), the ministerial operational steering committee for Health and the SGPI. The criteria fall into three categories:
- Quality of the candidate: major publications over the last ten years, prestigious invited lectures, discoveries that have changed knowledge or practice, international scientific prizes, high-impact patents or innovations where applicable, major scientific responsibilities (leading large projects, coordinating international networks, academies, editorial boards), peer support attested by three reference letters.
- Quality of the research proposal: ability to identify the major unresolved questions, to propose an original, even counter-intuitive, approach, to take justified scientific risks and to build a dedicated team (profiles sought, management approach). The evaluation covers the relevance of the project, the clarity of the objectives and hypotheses, its novelty and ambition, the successful applicant's role as project lead, the quality of the team if it is partly in place, the match between human and financial resources and objectives, the timetable, milestones and risk management, and the governance of the project.
- Impact and benefits: ability to disseminate and exploit the results towards the socio-economic world, to turn them into products and services in the field of emerging infectious diseases and health crisis preparedness, with measurable added value for health, and to support, where appropriate, transfer to industry or the creation of economic activities.
Points to watch
- As of 11 November 2026, the financial regulations, the submission website and the templates (scientific document, administrative and financial document, publications annex, reference letters) are listed as "coming soon": the eligible costs, which the financial regulations set, remain to be confirmed before finalising the budget.
- Strict admissibility: an application that is incomplete at the closing date is not evaluated. The administrative and financial document, signed by each partner institution and scanned, must be submitted before 28 January 2027 at 11:00, and no item is accepted after the closing date.
- Other admissibility criteria: CV and three reference letters from academic or industrial peers, a dozen years of career remaining in France, a scientific document of no more than 15 pages, in English, as an unprotected PDF, at least three of the call's six directions, a duration of no more than five years, funding of no more than €3.3 million, only one application per lead applicant.
- Consortium agreement: mandatory as soon as a company takes part, unless a framework contract already exists between the partner institutions, and to be provided within twelve months of the signature of the contract; the first instalment of the funding is conditional on its signature. It must make it possible to verify that no indirect aid is granted to companies.
- The aid may constitute State aid if it supports economic activities; the call text cites the applicable legal bases (2022 RDI framework, exempted framework scheme SA.111723, de minimis Regulation 2023/2831).
- Open science obligations (immediate open access under a CC-BY licence, deposit in HAL (the French open archive), first version of the data management plan within six months), acknowledgement of France 2030 support and annual monitoring indicators.
- The call text refers to the signatory institution in turn as "établissement d'accueil" (host institution), "gestionnaire" (managing institution) and "coordinateur" (coordinating institution). The web page says that successful applicants coming from abroad settle in a "public environment", whereas the admissibility rules also allow a private non-profit institution: to be clarified with ANR if the intended institution is private.
- The date of publication of the results and the start date of the chairs are not given in the call text: to be confirmed with ANR.
- Do not confuse the CSIV with the transnational health calls in the catalogue, such as ERA4Health: here, there is no funded international consortium, but an individual chair under an agreement with a French institution.
The CHOICE view
This call is aimed at universities, research organisations and healthcare institutions that want to attract or retain a leading figure in vaccinology and give them their own team, in a field where the call text stresses the need to renew academic leadership. With three to four chairs for the whole country, on criteria modelled on the ERC Advanced, it only suits a candidate whose record already stands up to international comparison. Even though the application is the researcher's, the institution commits a great deal: premises and access to platforms, administrative support, hosting capacity that can grow, and above all the prospect of a long-term settlement in France, reviewed at mid-term. For a team already in place, the question is also one of consistency with the roadmap of the unit and the site: graduate schools of research, PEPR, INBS, the I-REIVAC network, overseas France or international partnerships, since the project must cover at least three of the six directions.
CHOICE advises securing first the candidate's eligibility (remaining career, training experience, a single application), then the institution's written commitment and the signature process by its legal representative, to be completed before 28 January 2027 at 11:00, a period that includes the end-of-year holidays. An industrial partner is welcome, particularly on direction 2, but it is not funded and requires a consortium agreement on which the first instalment depends: it is best to outline its main intellectual property terms before submission. The budget will remain provisional until the financial regulations are published. Nothing guarantees that the chair will be awarded: an interview is possible and the final decision rests with the Prime Minister.
How to prepare your project
- Check the admissibility criteria with the candidate: at least a dozen years of career remaining in France, a track record at ERC Advanced level, experience in advanced training, a single application.
- Choose at least three of the call's six directions and position the project within the national strategy (PEPR, CATRIEM, I-REIVAC, graduate schools of research).
- Define the dedicated team (profiles sought, management approach), the timetable, the milestones and risk management over no more than five years.
- Have the heads of the host structures write the letter of commitment (laboratory space, infrastructure, administrative support) and formalise the solutions for the successful applicant's long-term settlement.
- Identify the partners (companies, foreign institutions, other institutions) and, if a company takes part, prepare the consortium agreement.
- Gather the CV, the list of publications from the last ten years and three reference letters from academic or industrial peers.
- Follow the call page for the publication of the financial regulations, the templates and the submission website, and open an account on that website as soon as possible.
- Write the scientific document (15 pages maximum, in English) and complete the administrative and financial document with the signed letters of commitment.
- Submit the complete application, including signed documents, before 28 January 2027 at 11:00 (Paris time). Administrative questions: France-Vaccins@anr.fr.
Official sources
- ANR: CSIV call page (French)
- ANR: CSIV call page (English version of the website)
- ANR: text of the 2026 France Vaccins call for applications (PDF)
The conditions of a scheme can change. This fact sheet was checked on the date shown; only the call specifications, the official texts and the funding body's decision are authoritative.
How CHOICE works on this kind of application
Finding the right scheme is only one step. What matters happens before: clarifying the project, gathering the expected evidence, bringing in the right partners and sequencing commitments.
- Our approach Improve and de-risk the project before financing it.
- Our services Assessment, business plan, preparing and filing the application, representation, follow-up.
- Our references More than 130 projects supported over ten years, and the firm's accreditations.
- Designing a funding trajectory Also worth reading in our publications.
- All academic research calls The full catalogue, with conditions and deadlines.